कंपनी का अवलोकन
Lucyd, Inc. operates within the healthcare sector, specifically focusing on the industry of medical instruments and supplies, although its product line primarily targets the consumer technology space with smart eyeglasses. The company is dedicated to the development and sale of smart eyeglasses and sunglasses in North America, offering flagship products like the Lucyd Lyte which enable hands-free functionality for music, calls, and voice assistant integration. The total market capitalization stands at $7.06M, supported by an annual revenue of $2.66M over the trailing twelve months and a workforce comprising 13 employees. These financial figures indicate that Lucyd, Inc. is a micro-cap entity with a relatively small balance sheet compared to established peers in the broader technology or healthcare sectors. The combination of a low market cap and modest revenue suggests the company is in an early-stage phase where capital allocation focuses on product development and market penetration rather than mature operational scaling.
वित्तीय स्वास्थ्य
The company reported a revenue of $2.66M for the trailing twelve months, yet it recorded a net income loss of $-7,591,189 and an EBITDA of $-8,359,622, revealing a significant structural gap between top-line growth and bottom-line profitability. This disparity indicates that the cost structure involves substantial operating expenses, likely related to R&D and sales infrastructure, which currently outpace the revenue generated from the sale of smart eyeglasses. Free cash flow stands at $-5,588,018, which implies that the company is burning cash and relies heavily on external financing or existing reserves to sustain operations without generating internal liquidity. On the asset side, the company holds $6.51M in cash and maintains zero debt, creating a distinct position where cash reserves exceed liabilities. The debt-to-equity ratio is effectively N/A due to the absence of debt, suggesting a balance sheet that is not leveraged but rather cash-rich despite the losses. The current ratio is 9.03, indicating an extremely high level of short-term liquidity where current assets significantly outweigh current liabilities. Return on Equity is -83.6% and Return on Assets is -53.2%, metrics that reveal management is currently unable to generate positive returns on the capital invested or the assets held. These negative return figures are characteristic of pre-profitability technology companies that are prioritizing long-term growth over immediate shareholder value accretion.
मूल्यांकन आकलन
The P/E Ratio (TTM) is N/A due to the lack of net income, while the Forward P/E is listed as -2.49, a metric that reflects the negative earnings expectation and implies that the market prices the stock based on future turnaround potential rather than current profitability. The price-to-book ratio is 0.68, indicating that the market values the company at less than its book value, which often occurs when investors discount the value of intangible assets or anticipate ongoing losses that will erode equity. The price-to-sales ratio stands at 2.65, and the EV/EBITDA is -0.07, suggesting that valuation multiples are being driven by revenue generation potential rather than earnings power. The stock has traded between a 52-week high of $5.56 and a 52-week low of $0.95, meaning the current valuation sits within a wide volatility band that reflects the high-risk nature of micro-cap biotech or tech plays. The beta value is 3.06, which indicates that the stock price is highly volatile and tends to fluctuate with significantly greater intensity than the broader market index. This high beta suggests that the stock is suitable only for investors with a high tolerance for price swings and uncertainty regarding the company's path to profitability.
Growth & Income
Revenue growth year-over-year is 39.0%, while earnings growth is N/A, indicating that the company is experiencing rapid top-line expansion but has not yet achieved consistent profitability to calculate meaningful earnings growth rates. The absence of a dividend yield and a 0.0% payout ratio confirms that the company does not distribute cash to shareholders, as it must retain all earnings to fund operations and development. Instead of paying dividends, the firm reinvests its financial resources, including the $6.51M cash on hand, directly into the development of smart eyeglasses and the expansion of its North American market presence. The overall growth and income profile characterizes Lucyd, Inc. as a pure growth vehicle with no current income distribution, where value creation is entirely dependent on the company's ability to transition from negative net income to positive profitability in the future.